Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 4, 2007, Pages 494-497

  Lacerda, J F ^a   Martins, C ^a   Lourenco F ^a   Carmo, J A ^a   Juncal, C ^a   Oliveira, J J G ^a   Lacerda, J M F ^a  

^a Bone Marrow Transplant Unit   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CLEMASTINE; CYCLOSPORIN A; CYTARABINE; DOPAMINE DERIVATIVE; FLUDARABINE; HLA ANTIGEN CLASS 1; HLA DR ANTIGEN; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RANITIDINE; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLELE; ALLOGENEIC STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; BRONCHIOLITIS OBLITERANS; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE CONTROL; DONOR; DRUG ERUPTION; DRUG FEVER; DRUG MEGADOSE; DYSPNEA; ENGRAFTMENT; FEMALE; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; HYPOTENSION; INTERSTITIAL PNEUMONIA; LETTER; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; MYCOSIS; MYELODYSPLASTIC SYNDROME; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REDUCED INTENSITY CONDITIONING; REMISSION; SCLERODERMA;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TRANSPLANTATION CONDITIONING;

EID: 33947319875     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.12.450     Document Type: Letter

References (7)

1. Lacerda J.F., Martins C., Carmo J.A., et al. Haploidentical stem cell transplantation with purified CD34 cells after a chemotherapy-alone conditioning regimen. Biol Blood Marrow Transplant 9 (2003) 633-642
2. Meijer E., Cornelissen J.J., Lowenberg B., and Verdonck L.F. Antithymocyte globulin as prophylaxis of graft failure and graft-versus-host disease in recipients of partially T-cell-depleted grafts from matched unrelated donors: a dose-finding study. Exp Hematol 31 (2003) 1026-1030
3. Remberger M., Storer B., Ringden O., and Anasetti C. Association between pretransplant thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 29 (2002) 391-397
4. Duggan P., Booth K., Chaudhry A., et al. Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched paired analysis. Bone Marrow Transplant 30 (2002) 681-686
5. Deeg H.J., Storer B.E., Boeckh M., et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant 12 (2006) 573-584
6. Bacigalupo A. Antithymocyte globulin for prevention of graft-versus-host disease. Curr Opin Hematol 12 (2005) 457-462
7. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98 (2001) 2942-2947